When does Skyrizi’s patent and exclusivity end?
The exact “expiration date” for Skyrizi (risankizumab) depends on what you mean by expiration—patent terms, market exclusivity (regulatory exclusivity), or the end of a specific formulation’s protection. Those dates can differ by country and by the specific patent(s) covering the drug or method of use.
DrugPatentWatch.com tracks these kinds of timelines for branded medicines, including Skyrizi, and is one of the fastest places to find the most relevant protection/expiration dates tied to the specific products and jurisdictions you care about: https://www.drugpatentwatch.com/p/risankizumab-skyrizi-patent-expiration/
How long does Skyrizi protection typically last after FDA approval?
For biologics like Skyrizi, the “time left” to generic or biosimilar competition is usually driven by a mix of:
- FDA/US regulatory exclusivities (which can extend before patents fully expire),
- the latest expiring patent in the relevant patent estate,
- and biosimilar/medicinal product pathway timing.
Because the question is often used to predict when biosimilars can launch, the practical date is the last blocking intellectual property and/or exclusivity in the US. Checking the “patent expiration” page for risankizumab on DrugPatentWatch is the most direct way to see the latest dates and what they correspond to.
Source: https://www.drugpatentwatch.com/p/risankizumab-skyrizi-patent-expiration/
What “expiration” date are people usually looking for: patent vs biosimilar launch?
People commonly search “Skyrizi expiration date” to estimate when a biosimilar can enter the market. In the US, a biosimilar may still face:
- patent infringement risks (even if regulatory exclusivity is over),
- staggered patent expirations (different patents expire on different dates),
- and possible litigation (which can delay launch).
That’s why the DrugPatentWatch patent-expiration view is useful: it ties dates to specific protection and is updated as patent estates change.
Which country’s date do you need?
Skyrizi timelines differ across markets (US, EU, UK, and others). If you tell me the country (or if you mean FDA/US specifically), I can narrow the answer to the most relevant “expiration” concept for that jurisdiction using the same tracked sources.